House votes to bar public funding for ED drugs

The U.S. House of Representatives voted on Friday to bar government insurance programs Medicare and Medicaid from paying for the erectile dysfunction (ED) drugs Viagra, Cialis and Levitra.
Currently, Medicaid spends approximately $15 million a year on ED drugs and the Congressional Budget Office predicts the government would spend $2 billion over 10 years on impotence treatments, once Medicare begins offering prescription drug coverage in 2006.
The bill must still pass in the Senate where a similar measure has also been introduced.
The pharmaceutical industry said it would work to keep the bill out of the Senate.
"Unfortunately, the House is telling these men (anti-impotence drug patients), 'Tough luck, you are on your own,' Ken Johnson, senior vice president of the Pharmaceutical Research and Manufacturers of America (PhRMA) told The New York Times. "Hopefully, the Senate will view this important health issue with a little more compassion."
In passing the bill, 100 Democrats joined with 185 Republicans to approve the measure by a final vote of 285 to 121.
The measure is part of an overall spending bill providing more than $600 billion for a wide array of health and education programs including money for the National Institutes of Health, student loans and programs to fight AIDS.

 

You must be a registered member of MMM to post a comment.

Email Newsletters


As US pharma continued its quest for a Grand Prix at the Lions Health international festival of creativity, MM&M went on location to Cannes, France. Missed our coverage from June? Now, we're giving you an opportunity to catch up on some of what you missed. Download our e-book on the two-day festival, recapping the event, rounding up the best of the speakers, offering perspective and listing all of the winners. Click here to download.


The most recent MM&M Skill Sets Live event surveyed a range of issues relating to one of the hottest promotional spaces in healthcare. Speakers and panelists at the morning-long session, including promotional- and multichannel-minded executives from GSK, Epocrates, Treato and Montefiore Medical Center, weighed in on topics designed to help marketers demystify the challenges associated with non-personal promotion. Click here.